Samsara Vision has announced a partnership with Medevise Consulting in order to support the Samsara Vision’s Tsert SI Implantable Miniature Telescope (IMT) (by Isaac Lipshitz). The two companies will collaborate to advance clinical research, coordinate reimbursement, and drive sales, marketing, and customer relationships.
The next generation IMT has received a Conformité Européene (CE) Mark in May 2020. The implantable device includes foldable haptics that allow the IMT to fit into the injector and be delivered through a smaller incision. The device has the identical optical elements of the currently available IMT (magnification of 2.7x). Therefore, the next generation IMT eases the surgical procedure, thereby reducing the risk for patient trauma while halving the surgery time (to about 25 minutes in normal cases).
“We’re excited to partner with Samsara Vision to introduce the next generation IMT to our provider community,” said Jérôme Marzinski, Chief Commercial Officer at Medevise, which is headquartered in Strasbourg, France. “Bringing new breakthrough, game-changing technologies in the European ophthalmic space is our mantra at Medevise. We are thrilled and excited to launch the Tsert SI IMT platform into key first-served European markets including Germany, France, Spain. This technology will dramatically improve late-stage AMD patients’ lives. We are confident that with our market intelligence and our close relationship with leading KOLs, this launch will be successful.”
Full press release: www.businesswire.com/news/home/20210309005946/en/Samsara-Vision-and-Medevise-Consulting-Announce-European-Partnership